Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    AMYOTROPHIC LATERAL SCLEROSIS 3
Show Display Options
Rank Status Study
1 Completed Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo;   Drug: MCI-186 in open label phase
2 Terminated Phase 3 Extension Study of Dexpramipexole in ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: Dexpramipexole
3 Completed A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: TCH346
4 Completed Phase 3 Study of Dexpramipexole in ALS
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole;   Drug: Placebo
5 Completed Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Memantine (Ebixa);   Drug: riluzole;   Drug: Placebo
6 Completed Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo of MCI-186
7 Recruiting A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral
Condition: Amyotrophic Lateral Sclerosis
Interventions: Other: Intravenous administration of placebo;   Drug: Intravenous administration of 1 million of MSC;   Drug: Intravenous administration of 2 million of MSC;   Drug: Intravenous administration of 4 million of MSC
8 Active, not recruiting The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Masitinib (AB1010);   Drug: Riluzole;   Drug: Placebo
9 Enrolling by invitation A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention: Drug: tirasemtiv
10 Active, not recruiting Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: tirasemtiv;   Drug: Placebo tablets
11 Active, not recruiting Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: ODM-109;   Drug: Placebo for ODM-109
12 Not yet recruiting Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)
Conditions: Amyotrophic Lateral Sclerosis;   Frontal Temporal Dementia
Interventions: Drug: Memantine;   Drug: Placebo (for Memantine)
13 Completed
Has Results
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Oxepa;   Dietary Supplement: Jevity 1.5;   Dietary Supplement: Jevity 1.0
14 Active, not recruiting Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
Condition: Sialorrhea
Interventions: Drug: MYOBLOC;   Other: PLACEBO

Study has passed its completion date and status has not been verified in more than two years.